{"entity":{"id":"nct07508761","kind":"trial","name":"IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Nanjing Immunophage Biotech Co., Ltd, now recruiting.","summary":"IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07508761 by Nanjing Immunophage Biotech Co., Ltd, with 52 participants planned, started 2026-06-16 and due to reach its primary completion in 2028-12-30. Interventions recorded: IPG7236 and Toripalimab Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07508761","url":"https://clinicaltrials.gov/study/NCT07508761"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07508761","phase":"1/2","setting":"A Phase I/II Multicenter, Non-randomized, Open-label, Dose Escalation and Expansion Study of IPG7236 Combined With Toripalimab Treatment of Advanced Solid Tumors in Adult Patients to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity","sponsor":"Nanjing Immunophage Biotech Co., Ltd","enrolled":52,"outcomes":[]},"route":"/trials/nct07508761/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"nanjing-immunophage-biotech","kind":"company","name":"Nanjing Immunophage Biotech","route":"/companies/nanjing-immunophage-biotech/"}]}}